Organigram Global (OGI) Non Operating Investment Income (2018 - 2026)

Organigram Global (OGI) posted quarterly Non Operating Investment Income of -$28.4 million for Q1 2026, up 13.65% year-on-year from -$25.0 million in Q1 2025, and down 62.24% on a QoQ basis from -$17.5 million in Q4 2025.

Organigram Global (OGI) Non Operating Investment Income (2018 - 2026) Analysis & Trends

Organigram Global (OGI) has reported Non Operating Investment Income for 6 consecutive years, with -$28.4 million the latest figure, recorded in Q1 2026.

  • Quarterly Non Operating Investment Income rose 13.65% year-over-year to -$28.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$68.4 million (down 448.79% YoY) and the FY2025 annual result came in at -$6539.7, down 101.41% from the prior year.
  • Non Operating Investment Income declined to -$28.4 million in Q1 2026 per OGI's latest filing, from -$17.5 million in the prior quarter.
  • Over the last five years, Non Operating Investment Income for OGI reached as high as $10.4 million in Q4 2024 and fell as low as -$32.9 million in Q1 2025.
  • A 4-year average of -$13.6 million and a median of -$17.5 million in 2025 frame the typical range for Non Operating Investment Income.
  • Annual changes were most pronounced in 2025 — Non Operating Investment Income plunged 268.57% — and 2026, when it increased 13.65%.
  • Year by year, Non Operating Investment Income stood at $237951.8 in 2023, then jumped by 4260.64% to $10.4 million in 2024, then tumbled by 268.57% to -$17.5 million in 2025, then sank by 62.24% to -$28.4 million in 2026.
  • According to Business Quant data, Non Operating Investment Income over the past three periods registered -$28.4 million, -$17.5 million, and -$32.9 million for Q1 2026, Q4 2025, and Q1 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn -
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn -
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn -
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn -
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn -
10 Organigram Global 121.15 Mn 154.23 Mn 28.97 Mn -28.38 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -28.38 Mn
Mar 31, 2026 -28.38 Mn
Dec 31, 2025 -17.49 Mn
Dec 31, 2025 -17.49 Mn
Mar 31, 2025 -32.86 Mn
Mar 31, 2025 -32.86 Mn
Dec 31, 2024 10.38 Mn
Dec 31, 2024 10.38 Mn
Sep 30, 2023 237,951.82
Sep 30, 2023 237,951.82
Feb 28, 2021 42.33 Mn
Feb 28, 2021 42.33 Mn
Nov 30, 2018 -246,000.00
Nov 30, 2018 -246,000.00